Bilgehan SOLMAZ, Özlem MERMUT, İbrahim Taşkın RAKICI, Cem LEBLEBİCİ
Acta Haematologica Oncologica Turcica - 2026;59(1):70-73
Anaplastic pleomorphic xanthoastrocytoma (APXA) is a rare World Health Organization (WHO) grade 3 glial neoplasm with limited long-term survival data. While grade 2 pleomorphic xanthoastrocytoma (PXA) demonstrates favorable 5-year overall survival rates of 80-90%, anaplastic variants carry a significantly worse prognosis with 5-year survival of approximately 55-57%. BRAF V600E mutations are detected in 50-78% of PXAs and have been associated with improved clinical outcomes; however, cases with follow-up exceeding 10 years are exceptionally rare in the literature, making long-term prognostic assessment challenging. We report an exceptional case of BRAF V600E-mutant APXA with 12-year disease-free survival following gross total resection and comprehensive multimodal adjuvant therapy.
